Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

Study acronym: SARCO-GYN
StatusTerminated
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: recruitement failure Show 5 more changesShow less
    • Final enrollment: 6 participants — 8% of the 75 planned
    • Primary completion date changed from estimate of Oct 2025 to Aug 1, 2024
    • Eligibility criteria expanded, about 10 words
    • Study description shortened, about 10 words
    • Site details revised
  2. Primary endpoints revised (2)v3
  3. Primary completion date: Apr 17, 2023 to Oct 2025v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological treatment. main question : Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria. Data collection will be done at 6 months, 12 months after the date of inclusion.
Trial Details
NCT Number NCT05833321
Lead Sponsor Centre Hospitalier Metropole Savoie
Conditions
(from sponsor)		 Ovarian Neoplasms, Sarcopenia
Related terms Ovarian Neoplasms, Sarcopenia
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov